WEP Clinical

Here's to another great year at WEP! Thank you to everyone who has worked with us to help make a difference and continue to be With Every Patient. We are looking forward to an even better year in 2025. #WithEveryPatient #ExpandedAccessPrograms #PostTrialAccess #CompassionateUse #DrugDevelopment #ClinicalTrials #Committment #CustomerService #Teamwork

🎄WEP Christmas Party 2024! 🎄 What an incredible evening celebrating the amazing mission and values of WEP Clinical. This company thrives on a culture of passion, care, and unwavering dedication—towards our patients, each other, and our shared drive to achieve the extraordinary. A well-deserved night of joy and celebration with a team that makes a difference. Wishing everyone a Merry Christmas and a Happy New Year! ❤️✨

Don’t miss WEP’s Head of Expanded Access Strategy, Ana Paula Tediosi, speaking at the World Economic Forum Annual Meeting, as part of a panel discussion being held at the Health Equity Lounge @ Davos, in January 2025. Together with representatives from NGOs (including Partners For Patients NGO), policymakers, and the pharmaceutical industry, Ana will co-chair this panel. The speakers will address the challenges pharmaceutical companies and regulators face in providing access to innovative medicines through compassionate use and expanded access programs to patients in low- and middle-income countries and explore strategies to surmount these obstacles.   Panel summary: Compassionate use represents a critical treatment pathway, permitting access to unapproved medications for life-threatening conditions when no other options exist. Under stringent conditions, investigational drugs may be made accessible to patient groups lacking satisfactory authorized treatments and ineligible for clinical trials, offering them a potential lifeline. However in low- and middle-income countries regions, the availability of innovative medicines through compassionate use is limited compared to Europe and the US.   Reach out to us if you would like to learn more or connect with Ana at the event! [email protected] #WorldEconomicForum #WEF25 #CompassionateUse #ExpandedAccess #WithEveryPatient 

Meet with the WEP team at JPM Week 2025, in San Francisco! Our COO, Shaheen Limbada, and our Head of Clinical Strategy, Brian-Patrick T., are looking forward to meeting with biotech and investors to discuss how WEP Clinical can help bring pipelines to the global market with economic and timeline efficiencies. If you would like to schedule a meeting, please reach out directly at: [email protected] See you all there! #WithEveryPatient #JPM2025

Regulatory Affairs is an essential pillar when managing global Expanded Access (EAP), Compassionate Use (CU), or Named Patient Programs (NPP). However, navigating this heterogeneous and, at times, ambiguous landscape can be challenging. Timelines, application procedures, and document requirements can vary significantly from country to country, impacting timely access to treatment.   WEP’s dedicated Regulatory team can help you navigate this landscape by leveraging our extensive global regulatory intelligence and experience to develop tailored strategies.   Check out our latest resource featuring an example regulatory assessment in 14 countries for a treatment access program. You can access the resource by clicking the link below: https://lnkd.in/dbpjcEKd And stay tuned next year for an in-depth article discussing the challenges and opportunities of navigating this complex regulatory landscape. #ExpandedAccess #CompassionateUse #NamedPatientPrograms #Regulatory #RegulatoryAffairs #Compliance #WithEveryPatient

🌟In the latest Wren Insights post, our Director of Project Management in Nursing, Kelly Nichols, explains how home nursing allows research sites to optimize for time and efficiency and focus on patient care and trial outcomes. During the article, Kelly discusses: 👩⚕️👨🏽⚕️How home nursing facilitates and manages visits to release the burden on hardworking site staff 📋🖊️How our project management team coordinates with sites to obtain accurate regulatory and source documents 🌡️🩺The importance of maintaining consistent care. Read the full piece below 👇 #homenursing #researchsites #homehealthsolutions

Check out our latest case study detailing how we helped a Sponsor set up and deliver a global paid-for Post-Approval Named Patient Program (PA-NPP), to supply its FDA-approved medicine to rare disease patients living outside the US. This strategically built program allowed the Sponsor to: - Provide a much-needed treatment option for patients around the world - Establish real world early clinical experience - Build a network of KOLs and advocates to support future clinical trials and launch efforts across Europe and ROW - Reinvest revenue to help develop the company’s infrastructure in Europe   Access the case study in full to find out more using the link below: https://lnkd.in/dnz2xK5S #NamedPatientProgram #NamedPatientUse #TreatmentAccess #WithEveryPatient

💡 Check out the latest content on our WEP Insights page.   This week, our Head of Expanded Access Strategy, Ana Paula Tediosi, outlines some crucial considerations for Sponsors that are thinking about switching access program vendors. At WEP, we have successfully guided numerous Sponsors in transitioning their access programs from the initial vendor to our services. Our expertise ensures a seamless transition process from start to finish, enabling Sponsor teams to redirect their internal resources toward clinical trials and commercialization efforts.   Visit the website to learn more on this and other important topics relating to drug development, treatment access and commercialization solutions from our Subject Matter Experts (SMEs).   https://lnkd.in/dPHm9wF3 #WEPInsights #WithEveryPatient #ExpandedAccess #PostTrialAccess #CompassionateUse #ManagedAccess #NamedPatient

Less than a week to go until the ASH Annual Meeting in San Diego! Don't miss your opportunity to connect with our WEP industry experts to talk about how we can support your hematology drug development and treatment access efforts. See you there! #ASH2024 #Hematology #WithEveryPatient

Have you checked out our latest downloadable resource? WEP’s Access Team has put together a useful document for Sponsors, outlining the key questions to consider when thinking through if and how to provide continued treatment access at the end of your clinical study. You can download this resource using the link below. Please feel free to reach out to us with any questions! https://lnkd.in/g28by3et #PostTrialAccess #ExpandedAccess #TreatmentAccess #WithEveryPatient